{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:20:23Z","timestamp":1790958023479,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rhythm Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bardet\u2013Biedl syndrome is a rare genetic disease associated with hyperphagia and early-onset, severe obesity. There is limited evidence on how hyperphagia and obesity affect health-related quality of life in patients with Bardet\u2013Biedl syndrome, and on how management of these symptoms may influence disease burden. This analysis evaluated changes in health-related quality of life in adults and children with Bardet\u2013Biedl syndrome in a Phase 3 trial following 1\u00a0year of setmelanotide treatment (ClinicalTrials.gov identifier: NCT03746522).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with Bardet\u2013Biedl syndrome and obesity received 52\u00a0weeks of treatment with setmelanotide and completed various self-reported health-related quality of life measures. Patients aged\u2009&lt;\u200918\u00a0years or their caregiver completed the Pediatric Quality of Life Inventory (PedsQL; meaningful improvement, 4.4-point change); adults aged\u2009\u2265\u200918\u00a0years completed the Impact of Weight on Quality of Life Questionnaire-Lite (IWQOL-Lite; meaningful improvement range, 7.7\u201312-point change). Descriptive outcomes were reported in patients with data both at active treatment baseline and after 52\u00a0weeks of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty patients (&lt;\u200918\u00a0years, n\u2009=\u20099;\u2009\u2265\u200918\u00a0years, n\u2009=\u200911) reported health-related quality of life at baseline and 52\u00a0weeks. For children and adolescents, PedsQL score mean change from baseline after 52\u00a0weeks was\u2009+\u200911.2; all patients with PedsQL impairment at baseline (n\u2009=\u20094) experienced clinically meaningful improvement. In adults, IWQOL-Lite score mean change from baseline was\u2009+\u200912.0. Of adults with IWQOL-Lite impairment at baseline (n\u2009=\u20098), 62.5% experienced clinically meaningful improvement. In adults, IWQOL-Lite score was significantly correlated with changes in percent body weight (<jats:italic>P<\/jats:italic>\u2009=\u20090.0037) and body mass index (<jats:italic>P<\/jats:italic>\u2009=\u20090.0098).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>After 1\u00a0year of setmelanotide, patients reported clinically meaningful improvements across multiple health-related quality of life measures. This study highlights the need to address the impaired health-related quality of life in Bardet\u2013Biedl syndrome, and supports utility of setmelanotide for reducing this burden.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> NCT03746522. Registered November 19, 2018, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03746522\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03746522<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02602-4","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T14:03:07Z","timestamp":1673877787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet\u2013Biedl syndrome: phase 3 trial results"],"prefix":"10.1186","volume":"18","author":[{"given":"Elizabeth","family":"Forsythe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Haws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Argente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel \u00c1.","family":"Martos-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Dollfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costel","family":"Chirila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Gnanasakthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieana C.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha G.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-4982","authenticated-orcid":false,"given":"Andrea M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"6","key":"2602_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/jmg.36.6.437","volume":"36","author":"PL Beales","year":"1999","unstructured":"Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet\u2013Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437\u201346.","journal-title":"J Med Genet"},{"key":"2602_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fped.2018.00023","volume":"6","author":"E Forsythe","year":"2018","unstructured":"Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet\u2013Biedl syndrome-now and in the future. Front Pediatr. 2018;6:23.","journal-title":"Front Pediatr"},{"issue":"2","key":"2602_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/PGE-13051","volume":"2","author":"S Castro-S\u00e1nchez","year":"2013","unstructured":"Castro-S\u00e1nchez S, \u00c1lvarez-Satta M, Valverde D. Bardet\u2013Biedl syndrome: a rare genetic disease. J Pediatr Genet. 2013;2(2):77\u201383.","journal-title":"J Pediatr Genet"},{"issue":"2","key":"2602_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ajhg.2015.04.023","volume":"99","author":"A Lindstrand","year":"2016","unstructured":"Lindstrand A, Frangakis S, Carvalho CM, Richardson EB, McFadden KA, Willer JR, et al. Copy-number variation contributes to the mutational load of Bardet\u2013Biedl syndrome. Am J Hum Genet. 2016;99(2):318\u201336.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2602_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cge.13367","volume":"95","author":"E Geets","year":"2019","unstructured":"Geets E, Meuwissen MEC, Van Hul W. Clinical, molecular genetics and therapeutic aspects of syndromic obesity. Clin Genet. 2019;95(1):23\u201340.","journal-title":"Clin Genet"},{"issue":"6","key":"2602_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41436-020-0761-1","volume":"22","author":"HE Shamseldin","year":"2020","unstructured":"Shamseldin HE, Shaheen R, Ewida N, Bubshait DK, Alkuraya H, Almardawi E, et al. The morbid genome of ciliopathies: an update. Genet Med. 2020;22(6):1051\u201360.","journal-title":"Genet Med"},{"issue":"1","key":"2602_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ejhg.2012.115","volume":"21","author":"E Forsythe","year":"2013","unstructured":"Forsythe E, Beales PL. Bardet\u2013Biedl syndrome. Eur J Hum Genet. 2013;21(1):8\u201313.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"2602_CR8","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/j.2047-6310.2013.00182.x","volume":"8","author":"R Sherafat-Kazemzadeh","year":"2013","unstructured":"Sherafat-Kazemzadeh R, Ivey L, Kahn SR, Sapp JC, Hicks MD, Kim RC, et al. Hyperphagia among patients with Bardet\u2013Biedl syndrome. Pediatr Obes. 2013;8(5):e64-67.","journal-title":"Pediatr Obes"},{"issue":"3","key":"2602_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0041-1731035","volume":"10","author":"S Malhotra","year":"2021","unstructured":"Malhotra S, Sivasubramanian R, Srivastava G. Evaluation and management of early onset genetic obesity in childhood. J Pediatr Genet. 2021;10(3):194\u2013204.","journal-title":"J Pediatr Genet"},{"issue":"2","key":"2602_CR10","doi-asserted-by":"publisher","first-page":"e12703","DOI":"10.1111\/ijpo.12703","volume":"16","author":"J Pomeroy","year":"2021","unstructured":"Pomeroy J, Krentz AD, Richardson JG, Berg RL, VanWormer JJ, Haws RM. Bardet\u2013Biedl syndrome: weight patterns and genetics in a rare obesity syndrome. Pediatr Obes. 2021;16(2):e12703.","journal-title":"Pediatr Obes"},{"issue":"3","key":"2602_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000445061","volume":"9","author":"H Huvenne","year":"2016","unstructured":"Huvenne H, Dubern B, Clement K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158\u201373.","journal-title":"Obes Facts"},{"key":"2602_CR12","doi-asserted-by":"publisher","first-page":"e856","DOI":"10.7717\/peerj.856","volume":"3","author":"FT Yazdi","year":"2015","unstructured":"Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: back and forth, and back again. PeerJ. 2015;3:e856.","journal-title":"PeerJ"},{"issue":"1","key":"2602_CR13","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41467-019-08737-6","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang Y, van der Klaauw AA, Zhu L, Cacciottolo TM, He Y, Stadler LKJ, et al. Steroid receptor coactivator-1 modulates the function of POMC neurons and energy homeostasis. Nat Commun. 2019;10(1):1718.","journal-title":"Nat Commun"},{"issue":"7","key":"2602_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/hmg\/ddp031","volume":"18","author":"S Seo","year":"2009","unstructured":"Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet\u2013Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18(7):1323\u201331.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2602_CR15","doi-asserted-by":"publisher","first-page":"e1005890","DOI":"10.1371\/journal.pgen.1005890","volume":"12","author":"DF Guo","year":"2016","unstructured":"Guo DF, Cui H, Zhang Q, Morgan DA, Thedens DR, Nishimura D, et al. The BBSome controls energy homeostasis by mediating the transport of the leptin receptor to the plasma membrane. PLoS Genet. 2016;12(2):e1005890.","journal-title":"PLoS Genet"},{"key":"2602_CR16","unstructured":"Forsyth RL, Gunay-Aygun M. Bardet\u2013Biedl syndrome overview. In: GeneReviews. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1363\/. Accessed 10 Aug 2022."},{"key":"2602_CR17","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.conctc.2021.100780","volume":"22","author":"RM Haws","year":"2021","unstructured":"Haws RM, Gordon G, Han JC, Yanovski JA, Yuan G, Stewart MW. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alstrom syndrome: phase 3 trial design. Contemp Clin Trials Commun. 2021;22:100780.","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"2602_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709\u201357.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2602_CR19","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1210\/jc.2007-2458","volume":"93","author":"GP August","year":"2008","unstructured":"August GP, Caprio S, Fennoy I, Freemark M, Kaufman FR, Lustig RH, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93(12):4576\u201399.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2602_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11892-020-01327-7","volume":"20","author":"N Vos","year":"2020","unstructured":"Vos N, Oussaada SM, Cooiman MI, Kleinendorst L, Ter Horst KW, Hazebroek EJ, et al. Bariatric surgery for monogenic non-syndromic and syndromic obesity disorders. Curr Diab Rep. 2020;20(9):44.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"2602_CR21","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/oby.23385","volume":"30","author":"MG Gantz","year":"2022","unstructured":"Gantz MG, Driscoll DJ, Miller JL, Duis JB, Butler MG, Gourash L, et al. Critical review of bariatric surgical outcomes in patients with Prader\u2013Willi syndrome and other hyperphagic disorders. Obesity (Silver Spring). 2022;30(5):973\u201381.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"2602_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/chi.2021.0003","volume":"17","author":"AM Haqq","year":"2021","unstructured":"Haqq AM, Kebbe M, Tan Q, Manco M, Salas XR. Complexity and stigma of pediatric obesity. Child Obes. 2021;17(4):229\u201340.","journal-title":"Child Obes"},{"issue":"1","key":"2602_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","volume":"16","author":"M Arnold","year":"2015","unstructured":"Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2602_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/oby.2001.4","volume":"9","author":"ES Ford","year":"2001","unstructured":"Ford ES, Moriarty DG, Zack MM, Mokdad AH, Chapman DP. Self-reported body mass index and health-related quality of life: findings from the behavioral risk factor surveillance system. Obes Res. 2001;9(1):21\u201331.","journal-title":"Obes Res"},{"issue":"2","key":"2602_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/pubmed\/fdi025","volume":"27","author":"H Jia","year":"2005","unstructured":"Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf). 2005;27(2):156\u201364.","journal-title":"J Public Health (Oxf)"},{"key":"2602_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fpsyg.2019.01409","volume":"10","author":"X Ramos Salas","year":"2019","unstructured":"Ramos Salas X, Forhan M, Caulfield T, Sharma AM, Raine KD. Addressing internalized weight bias and changing damaged social identities for people living with obesity. Front Psychol. 2019;10:1409.","journal-title":"Front Psychol"},{"issue":"14","key":"2602_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.289.14.1813","volume":"289","author":"JB Schwimmer","year":"2003","unstructured":"Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA. 2003;289(14):1813\u20139.","journal-title":"JAMA"},{"key":"2602_CR28","doi-asserted-by":"publisher","first-page":"167520","DOI":"10.1100\/2012\/167520","volume":"2012","author":"A Sirtori","year":"2012","unstructured":"Sirtori A, Brunani A, Villa V, Berselli ME, Croci M, Leonardi M, et al. Obesity is a marker of reduction in QoL and disability. Sci World J. 2012;2012:167520.","journal-title":"Sci World J"},{"issue":"7","key":"2602_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/atm.2017.03.107","volume":"5","author":"M Abdelaal","year":"2017","unstructured":"Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161.","journal-title":"Ann Transl Med"},{"issue":"10","key":"2602_CR30","doi-asserted-by":"publisher","first-page":"e0140705","DOI":"10.1371\/journal.pone.0140705","volume":"10","author":"B Hamlington","year":"2015","unstructured":"Hamlington B, Ivey LE, Brenna E, Biesecker LG, Biesecker BB, Sapp JC. Characterization of courtesy stigma perceived by parents of overweight children with Bardet\u2013Biedl syndrome. PLoS ONE. 2015;10(10):e0140705.","journal-title":"PLoS ONE"},{"issue":"1","key":"2602_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-022-02186-z","volume":"17","author":"P K\u00fchnen","year":"2022","unstructured":"K\u00fchnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, et al. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38.","journal-title":"Orphanet J Rare Dis"},{"key":"2602_CR32","doi-asserted-by":"publisher","first-page":"S592","DOI":"10.1016\/j.jval.2019.09.991","volume":"22","author":"E Estrada","year":"2019","unstructured":"Estrada E, Knox J, Reed C, Hadker N, Fay M, McCagg A. PDB109: burden of illness associated with hyperphagia and severe obesity. Value Health. 2019;22:S592.","journal-title":"Value Health"},{"key":"2602_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-022-02059-8","volume":"39","author":"M Wabitsch","year":"2022","unstructured":"Wabitsch M, Fehnel S, Mallya UG, Sluga-O\u2019Callaghan M, Richardson D, Price M, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR deficiencies. Adv Ther. 2022;39:1\u201312.","journal-title":"Adv Ther"},{"key":"2602_CR34","unstructured":"Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Haqq AM, et al. Patient- and caregiver-reported experiences of hyperphagia in Bardet-Biedl syndrome before and during setmelanotide treatment. In: Presented at the pediatric endocrine society annual meeting; 2022 April 28\u2013May 1; virtual."},{"issue":"11","key":"2602_CR35","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/dom.14133","volume":"22","author":"R Haws","year":"2020","unstructured":"Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet\u2013Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2602_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","volume":"10","author":"AM Haqq","year":"2022","unstructured":"Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859\u201368. https:\/\/doi.org\/10.1016\/S2213-8587(22)00277-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2602_CR37","unstructured":"Imcivree (setmelanotide) [package insert]. Boston: Rhythm Pharmaceuticals, Inc.; 2022."},{"key":"2602_CR38","unstructured":"Varni JW. Scaling and scoring of the Pediatric Quality of Life Inventory: PedsQL. Version 20. Mapi Research Trust. https:\/\/www.pedsql.org\/PedsQL-Scoring.pdf. Accessed 18 Mar 2022."},{"issue":"8","key":"2602_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"issue":"6","key":"2602_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","volume":"3","author":"JW Varni","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329\u201341.","journal-title":"Ambul Pediatr"},{"issue":"11","key":"2602_CR41","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jclinepi.2004.04.004","volume":"57","author":"RD Crosby","year":"2004","unstructured":"Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153\u201360.","journal-title":"J Clin Epidemiol"},{"issue":"10278","key":"2602_CR42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"key":"2602_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1477-7525-5-43","volume":"5","author":"JW Varni","year":"2007","unstructured":"Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories\/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2602_CR44","doi-asserted-by":"publisher","first-page":"e200643","DOI":"10.1001\/jamanetworkopen.2020.0643","volume":"3","author":"N Marschner","year":"2020","unstructured":"Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A, et al. Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer. JAMA Netw Open. 2020;3(3):e200643.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2602_CR45","doi-asserted-by":"publisher","first-page":"19595","DOI":"10.1038\/s41598-019-56102-w","volume":"9","author":"TR Oh","year":"2019","unstructured":"Oh TR, Choi HS, Kim CS, Bae EH, Oh YK, Kim YS, et al. Association between health related quality of life and progression of chronic kidney disease. Sci Rep. 2019;9(1):19595.","journal-title":"Sci Rep"},{"issue":"3","key":"2602_CR46","doi-asserted-by":"publisher","first-page":"e200388","DOI":"10.1001\/jamanetworkopen.2020.0388","volume":"3","author":"HM Buiting","year":"2020","unstructured":"Buiting HM, Olthuis G. Importance of quality-of-life measurement throughout the disease course. JAMA Netw Open. 2020;3(3):e200388.","journal-title":"JAMA Netw Open"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02602-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T15:06:38Z","timestamp":1673881598000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2602"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02602-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was conducted in accordance with the International Council on Harmonisation for Good Clinical Practice and the Declaration of Helsinki. Institutional review board or independent ethics committee approval was obtained at all trial sites. Patients or guardians provided informed consent. Patient confidentiality was maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EF has received consulting fees from Rhythm Pharmaceuticals, Inc., and participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc., and she is a clinical investigator for clinical trials of setmelanotide in BBS for Rhythm Pharmaceuticals, Inc. RMH has received study drugs, grant support for clinical trials of setmelanotide in obesity, payments for lectures, and support for attending meetings from Rhythm Pharmaceuticals, Inc., as well as consulting fees from Rhythm Pharmaceuticals, Inc., and Axovia Therapeutics, LLC, and he participated in the data safety monitoring board for setmelanotide clinical trials for Rhythm Pharmaceuticals, Inc. JA has received payment for lectures from and participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc. PB is an NIHR senior investigator. G\u00c1MM has received payment for lectures\u00a0from and participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc. HD received consulting fees once from Rhythm Pharmaceuticals, Inc, and she has participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc. CC\u2019s institution received funding for this research from Rhythm Pharmaceuticals. AG\u2019s institution received funding for this research from Rhythm Pharmaceuticals. BCB is an employee of and stockholder in Rhythm Pharmaceuticals, Inc. UGM is an employee of and stockholder in Rhythm Pharmaceuticals, Inc. KC has received grant funding from Ysopia Bioscience, Integrative Phenomics, and Confo Therapeutics and is a clinical investigator for clinical trials of setmelanotide in BBS for Rhythm Pharmaceuticals, Inc. AMH has received grant funding from the Weston Family Microbiome Initiative and Canadian Institutes of Health Research, has received payment as a speaker for Pfizer Canada, Inc., is a member of the BBS advisory board for Rhythm Pharmaceuticals, Inc., and is a member of the 2022 somatrogon advisory board for Pfizer, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}